FG
NKTR icon

Formula Growth’s Nektar Therapeutics NKTR Stock Holding History

Formula Growth’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,087
Closed -$994K – 148
2018
Q3 		$994K Hold
1,087
– – 0.11% 128
2018
Q2 		$796K Sell
1,087
-360
-25% -$415K 0.09% 138
2018
Q1 		$2.31M Sell
1,447
-993
-41% -$1.28M 0.27% 78
2017
Q4 		$2.19M Sell
2,440
-333
-12% -$197K 0.29% 70
2017
Q3 		$998K Hold
2,773
– – 0.16% 120
2017
Q2 		$813K Hold
2,773
– – 0.14% 119
2017
Q1 		$976K Sell
2,773
-334
-11% -$75.1K 0.2% 119
2016
Q4 		$572K Hold
3,107
– – 0.13% 128
2016
Q3 		$801K Sell
3,107
-893
-22% -$230K 0.18% 138
2016
Q2 		$854K Hold
4,000
– – 0.21% 129
2016
Q1 		$825K Hold
4,000
– – 0.2% 128
2015
Q4 		$1.01M Buy
+4,000
New +$823K 0.24% 120

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Formula Growth's NKTR Position: Q4 2018 in Review

Formula Growth sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 1,087 shares — an estimated $994K sold.

Formula Growth first reported a position in NKTR in Q4 2015 and held it in 12 quarters. The position peaked at $2.31M in Q1 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Formula Growth reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Formula Growth sold 1,087 Nektar Therapeutics shares in Q4 2018, an estimated $994K.
  • Formula Growth first reported a position in Nektar Therapeutics in Q4 2015 and held it in 12 quarters.
  • Formula Growth's Nektar Therapeutics position peaked at $2.31M in Q1 2018.
  • 342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Formula Growth's 13F filing for Q4 2018, filed 14 Feb 2019.